tbuckley/cabot-search huggingface dataset:
Small-Bowel Endoscopy
Authors: F. P. Rossini, M. Pennazio
Journal: Endoscopy (2002)

During the last year, promising results with the first clinical applications of capsule endoscopy have been reported; this is a new, revolutionary diagnostic method for endoscopic study of the small bowel. The method has chiefly been used in patients with obscure gastrointestinal bleeding, and in some cases has allowed additional diagnoses to be made in comparison with push enteroscopy, with a positive influence on patient management. New therapeutic possibilities have also been developed in push enteroscopy, emphasizing the role of this technique as an essential component of gastrointestinal endoscopy. Important innovations in enteroscopy technique have been described, aimed at increasing the depth of examination, and these will probably make it possible to extend endoscopic treatments to include the entire small bowel. Finally, numerous articles are still being published concerning intraoperative enteroscopy. It is to be hoped that, in future, the use of this invasive procedure will be based on data acquired by capsule endoscopy.
Diseases of Women: A Treatise on the Principles and Practice of Gynecology for Students and Practitioners.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Candida albicans infection of an arteriovenous graft used for hemodialysis
Authors: D. S. Berman
Journal: JAMA (1987)

<h3>In Reply.—</h3> We concur with Dr Afable's comments and support his efforts to place ambulatory training on firmer financial ground. We neglected to discuss finances because the cost implications of our reorganization were the specific subject of a previous article.<sup>1</sup> We also agree with the observation by Taylor et al that academic group practices are not new, as indicated by our inclusion of six references to such organizations dating back to 1974. What was innovative about our own experience with group practice was our ability to evaluate clinic operation with the most rigorous of research designs. We believe that health services interventions should be held to the same standards of proof of effectiveness that are applied to proposed changes in clinical practice. Now that supportive data are at hand, we hope that other academic clinics will be persuaded to join family practice centers and general internal medicine programs in
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
Authors: Herbert Aaron Eradat, Tadeusz Robak, Julio Delgado, Anna Schuh, Alexander S. Pristupa, Joanna Omyla-Staszewska, Jacqueline Claudia Barrientos, Charles Michael Farber, Donald MacDonald, Abraham Jacob, Jeff Porter Sharman, Javier Loscertales, Jennifer R. Brown, Bertrand Coiffier, Paolo Ghia, Andrew David Zelenetz, Shelley Evans, Thomas Michael Jahn, Michael J. Hallek, Peter Hillmen
Journal: Journal of Clinical Oncology (2014)

TPS7127 Background: PI3Kδ is critical for the activation, proliferation and survival of B cells and plays a role in homing and retention of B cells in lymphoid tissues. PI3K signaling is hyperactive in many B-cell malignancies. Idelalisib is a first-in-class, selective, oral inhibitor of PI3Kδ that reduces proliferation, enhances apoptosis, and alters trafficking of malignant B cells in lymphoid tissues (Lannutti, 2011). Phase 1 trials demonstrated that idelalisib is highly active in heavily pretreated pts with CLL as a single agent or in combination with rituximab (R), bendamustine (B), or BR: pts experienced reductions in disease-associated chemokines, profound and rapid reductions in lymphadenopathy, and durable clinical benefit with an acceptable safety profile (Sharman et al, 2011; Coutre et al, 2012; Furman et al, 2014). Methods: Study will enroll 390 pts with previously treated CLL who have measurable lymphadenopathy, have received prior therapy containing a purine analog or B and an anti-CD20 monoclonal antibody, are not refractory to B, have experienced CLL progression within 36 months from the completion of the last prior therapy, and are currently sufficiently fit to receive cytotoxic therapy. Pts will be randomized in a 1:1 ratio to Arm A or B of the study. On Arm A, subjects will receive idelalisib continuously at 150 mg BID + R at 375 mg/m2 (1st dose) and then 500 mg/m2 every 4 weeks for 6 cycles + B at 70 mg/m2 on Days 1 & 2 of each 4-week cycle for 6 cycles. On Arm B, subjects will receive placebo instead of idelalisib. Stratification factors include IGHV mutational status, del17p/p53 mutation status, and refractory/relapsed status. The primary endpoint is PFS and key secondary endpoints include ORR, lymph node response rate, CR rate, and OS. This is an event-driven trial and primary endpoint evaluation will be based on independent central review. For the primary efficacy analysis, the difference in PFS between the treatment arms will be assessed in the ITT analysis set. The study was initiated in June 2012. Clinical trial information: NCT01569295.
A Text-Book On The Therapeutic Action Of Light.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Social Organization of Sexuality
Authors: D. Peter Drotman
Journal: JAMA (1995)

<h3>To the Editor.</h3> —The National Health and Social Life Survey on adult sexual behavior in the United States was released recently.<sup>1-3</sup>The report is based on interviews of 3432 men and women aged 18 to 59 years residing in randomly selected households across the country. The goals of the survey were to present a comprehensive and scientific picture of sexual behavior, guide further research, and target health and social services. However, the potential for misinterpretation of this information is great, particularly in planning and allocating resources related to sexually transmitted diseases such as the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS). One prominent finding of the survey was that approximately 80% of adults reported no or one sexual partner in the year before the interview, and approximately 3% of men and 2% of women reported any homosexual or bisexual activity during the same period. From these data,
Homosexuality. IV. Psychiatric Disorders and Disability in the Female Homosexual
Authors: MARCEL T. SAGHIR, ELI ROBINS, BONNIE WALBRAN, KATHYE A. GENTRY
Journal: American Journal of Psychiatry (1970)

A study of 57 homosexual women and 43 single heterosexual controls revealed slightly more clinically significant changes and disability in the lives of the homosexual women as compared with the heterosexual women. The chief differences were in the increased prevalence of alcoholism and of attempted suicide. Despite these difficulties, the homosexual women were able to achieve, adapt, and be productive citizens.
Abstract LB-030: Interferon signaling contributes to prostate cancer drug resistance
Authors: Supreet Agarwal, Kerry McGowen, Fathi Elloumi, Maggie Cam, Mike Beshiri, Eva Corey, Kathleen Kelly
Journal: Cancer Research (2019)

Abstract Contrary to the anti-proliferative interferon (IFN) signaling, IFN related DNA damage resistance signature (IRDS) has pro-survival function and is responsible for cancer cell intrinsic therapy resistance. This signature encompasses a subset of STAT1-driven genes that have been associated with breast cancer therapy resistance. Interestingly, our RNAseq analysis of organoids from FACS-sorted Pten/Tp53-null PCa luminal progenitors have revealed a robust IRDS expression. Based on our previous findings that the luminal progenitors display intrinsic resistance to androgen deprivation therapy (ADT), we hypothesized that the IRDS expression might in part account for survival of PCa cells following ADT or genotoxic therapies. Our analysis of human PCa datasets revealed IRDS as a prognostic marker for progression in the TCGA primary PCa cohort (p&amp;lt;0.05). Further, high IRDS-expressing castrate resistance PCa (CRPC) patients in SU2C dataset were enriched for low AR signaling (r= -0.33, p&amp;lt; 0.05). Patients in IRDS-hi cohort showed enrichment for stem cell phenotype and for gene-sets associated with therapy resistance. In line with our analysis of clinical samples, real time PCR, immunofluorescence and western blot analysis of organoid cultures initiated from castration-resistant Pten/Tp53-nulltumor progenitors showed high levels of unphoshorylated STAT1 (U-STAT1) in tumor luminal organoids than WT organoids whereas pSTAT1 (Y701) was not detectable. Similarly, U-STAT1 was overexpressed in Pten/Tp53-null tumor relative to the WT tissue. Knockdown of STAT1 in tumor organoids decreased number of progeny organoids in subsequent generations suggesting either a direct or indirect effect upon self-renewal of luminal tumor stem cells. Altogether, U-STAT1 regulated signaling has pro-survival function in Pten/Tp53-null advanced PCa. Several PDXs originating from metastatic PCa express high levels of U-STAT1 dependent IFN signaling. STAT1 depletion in 5 tested PDXs significantly reduced self-renewing ability of PDX derived organoids, consistent with mouse luminal tumor organoids. Interestingly, STAT1 depletion synergized with sensitivity to chemotherapy ex vivo. These findings indicate that U-STAT1 dependent IFN signaling may contribute to treatment resistance. Overall, our findings suggest U-STAT1 dependent IRDS is correlated with poorly differentiated PCa and IRDS expression in part accounts for intrinsic therapy resistance in prostate cancer. Citation Format: Supreet Agarwal, Kerry McGowen, Fathi Elloumi, Maggie Cam, Mike Beshiri, Eva Corey, Kathleen Kelly. Interferon signaling contributes to prostate cancer drug resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-030.
Estrogenic Activity of Phenolic Additives Determined by an In Vitro Yeast Bioassay
Authors: Danielle Miller, Brian B. Wheals, Nicola Beresford, John P. Sumpter
Journal: Environmental Health Perspectives (2001)

In the early 1970s, the largest industrial accident in the United States resulted in widespread contamination of the food supply in Michigan with polybrominated biphenyls (PBBs). The chemical similarity of PBBs to compounds implicated as endocrine disruptors has raised the question of whether PBBs could affect the reproductive system. In the present analysis we examine the relation between serum measurements of PBBs and the frequency and duration of lactation. Persons who lived on or received food from farms exposed to PBBs were enrolled in a registry by the Michigan Department of Public Health. Female members of the cohort were invited to participate in a telephone survey of reproductive outcomes. The three outcomes of interest in the present analysis were a) the decision to breast-feed (yes/no); b) the duration, in months, of breast-feeding as the main source of nutrition; and c) the total duration, in months, of breast-feeding. None of the three outcomes was significantly associated with serum PBB levels, even after controlling for maternal age, previous history of breast-feeding, body mass index, maternal education, household income, history of smoking in the year before pregnancy, consumption of alcohol during the first trimester of pregnancy, history of thyroid disorder, gestational age of the infant in weeks, time to pregnancy, and year of birth.
Smallpox
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neurological complications now characterizing many AIDS victims
Authors: P. Gapen
Journal: JAMA (1982)

As more and more cases of the mysterious acquired immunodeficiency syndrome (AIDS) are being diagnosed (<i>JAMA</i>[MEDICAL NEWS] 1982;248:1423-1431), medical researchers are developing a clearer picture of its clinical course. According to the Centers for Disease Control, Atlanta, as of Nov 19, 744 AIDS cases had been reported for the United States, with 287 deaths. So far, 54 cases have been reported from foreign countries. Among the latest findings are neurological complications in large numbers of AIDS patients, many of whom are homosexuals and/or intravenous drug abusers. At UCLA School of Medicine, neurological involvement is seen in three of every four AIDS patients, says Sandra L. Horowitz, MD, now of St Vincent's Hospital, Worcester, Mass. According to her, the complications "tend to arrive late and to be quite devastating" in Southern California victims. During the recent American Neurological Association (ANA) meetings in Washington, DC, Carolyn Britton, MD, of Columbia University
Der Bandschaden des Kniegelenks.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
INTEREPIDEMIC INFLUENZA
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply:
Authors: Savino Bruno, Patrick Maisonneuve, Mario U. Mondelli
Journal: Hepatology (2007)

In a study of similar design conducted in the same geographical area, Sangiovanni and colleagues1 did not find an association between genotype and risk of hepatocellular carcinoma (HCC) in compensated cirrhosis caused by chronic hepatitis C virus (HCV) infection. Although sample size, duration of surveillance, and number of events were approximately similar to our study, the proportion of patients lost to follow-up was much larger in their study [66 of 214 patients (31%) versus 20 of 163 patients (12%), respectively]. This may have affected their results because the development of HCC could have been the reason for dropout in some patients. Inclusion of patients with concomitant chronic hepatitis B virus (HBV) infection, which is known to confer a higher cancer risk,2 could have also obscured the association of HCC with genotype. Finally, in the absence of detailed information regarding HCV genotype, the mere statement of a lack of "statistical" significance in their study is quite difficult to interpret. In our study, none of the patients were coinfected with HBV. In addition, a conservative analysis performed assuming that all patients infected with genotype 2a/c who were lost to follow-up had developed HCC, whereas no one with genotype 1b did, showed that HCV genotype 1b remained significantly associated with HCC development. Although we previously mentioned that patients with HCV genotype 1b should be more aggressively monitored for occurrence of HCC, we agree with Sangiovanni and Iavarone that similar ultrasound surveillance intervals appear to be adequate for both patient groups, as recommended by international guidelines. Still, clinicians should be aware of the potentially higher oncogenic risk of genotype 1b in addition to other recognized risk factors and, to this end, it would be reasonable to recommend a more careful follow-up of these patients. This concept is strengthened by recent evidence showing that specific conformational features of the secondary structure of the N-terminus of the NS3 protein, characteristics of certain strains of HCV type 1b, are associated with an increased risk of HCC,3 thus providing a plausible pathogenetic basis for our findings. Savino Bruno*, Patrick Maisonneuve , Mario U. Mondelli , * Liver Unit, Department of Medicine, Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milan, Italy, Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy, Centre for Hepatology and Research Laboratories, Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy.
The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+T lymphocytes by human blood dendritic cells in vitro
Journal: Journal of Clinical Investigation (1993)

The text in the right hand column, lines 29-32, should read: The resulting interface was collected and washed twice in decreasingly hypertonic medium (L 1 34 g and 1.043 g total Na' per 100 ml RPMI-5% FCS) before a final wash in isotonic RPMI-5% FCS (20).
Single-source financing systems. A solution for the United States?
Authors: R. B. Saltman
Journal: JAMA (1992)

Although tax-based and social insurance—based forms of single-source financing differ in how they raise funds, they share a common set of structural characteristics. In particular, they both enable publicly accountable authorities to control aggregate expenditure levels by creating a countervailing power to pressures for increased expenditures from providers. While major reform initiatives are under way in European single-source financing systems, these initiatives have so far sought to improve the efficiency, effectiveness, and/or responsiveness to patterns of service delivery without reducing their commitment to universal access to necessary care. The article concludes with a review of the advantages and disadvantages that could accompany the introduction of a single-source financing system in the United States. (<i>JAMA</i>. 1992;268:774-779)
Gastroenterology
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal